Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 2

Conditions

Breast Neoplasms 291Carcinoma, Non-Small-Cell Lung 206Prostatic Neoplasms 158Lung Neoplasms 93Stomach Neoplasms 69Neoplasms 69Head and Neck Neoplasms 60Squamous Cell Carcinoma of Head and Neck 56Neoplasm Metastasis 50Esophageal Neoplasms 49Ovarian Neoplasms 39Pancreatic Neoplasms 26Sarcoma 23Carcinoma, Ovarian Epithelial 20Urinary Bladder Neoplasms 19Unspecified Adult Solid Tumor, Protocol Specific 19Breast Neoplasms, Male 17Adenocarcinoma Of Esophagus 17Parkinson Disease 4, Autosomal Dominant Lewy Body 16Esophageal Squamous Cell Carcinoma 16Adenocarcinoma of Lung 16Fallopian Tube Neoplasms 14Carcinoma, Squamous Cell 14Adenocarcinoma 12Melanoma 11Inflammatory Breast Neoplasms 11Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Salivary Gland Neoplasms 8Endometrial Neoplasms 8

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1pazopanib 1ixabepilone 1Thalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Recurrent Uterine Corpus Sarcoma × Docetaxel × Clear all
NCT00114218 2019-01-08

Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer

GOG Foundation

Phase 2 Completed
28 enrolled 7 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

NCT00031629 2016-12-08

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

GOG Foundation

Phase 2 Completed
51 enrolled
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡